When Was Mounjaro Released in the UK — and What Happened Next

The moment you probably searched for: what the approval date actually means

You've likely seen Mounjaro mentioned in the press and wondered whether it was genuinely available in the UK or still going through regulatory hoops. The short answer is that it has been fully licensed here since late 2023. Eli Lilly received MHRA approval for tirzepatide as a type 2 diabetes treatment in the spring of 2023, and the weight-management indication followed in November that year. From that point it could legally be prescribed in the UK by a qualified prescriber, supplied through a licensed pharmacy, and dispensed to adults who met the clinical criteria.

What the approval date does not mean is that it became instantly available on the NHS to everyone who wanted it. Licensing and NHS commissioning are separate processes, each with their own timelines. Plenty of people find that distinction confusing, and it's worth understanding the difference before assuming the treatment is (or isn't) within reach.

The MHRA's approval was based on a substantial body of evidence, including the SURMOUNT clinical programme. The headline finding most people remember comes from SURMOUNT-1: around 20–21% average body-weight reduction over 72 weeks at the 15 mg dose, in adults with obesity who did not have type 2 diabetes. The tirzepatide overview on this site covers those results in more detail.

How tirzepatide moved from approval to the pharmacy shelf

After the MHRA approved Mounjaro for weight management, Eli Lilly moved to make it available through UK supply channels. Private prescriptions became the first practical route: a qualified prescriber could assess someone, write a prescription, and a GPhC-registered pharmacy could dispense it. That's the route that remains available today for people who don't want to wait for NHS access or who don't meet the NHS eligibility criteria.

The NHS timeline took longer. NICE published its appraisal of tirzepatide (guidance reference TA1026) in December 2024, recommending the medicine for adults with a BMI of 35 or above and at least one weight-related comorbidity. NHS England then began a phased rollout: from June 2025, the highest-priority group (BMI 40 or above, four or more qualifying conditions) could access it through GP practices that had signed up to the new prescribing arrangements. A second cohort opened in June 2026, covering adults with a BMI of 35 to 39.9 with four or more qualifying conditions.

If you're curious about where your own situation sits, the full release date timeline page lays out each NHS phase clearly. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, and the rollout criteria reflect that throughout.

What changed between the drug being invented and it reaching UK patients

Tirzepatide's origins go back to Eli Lilly's research into gut-hormone pathways in appetite regulation. The molecule targets two receptors (GIP and GLP-1) rather than the single GLP-1 pathway that earlier medicines like semaglutide act on. Early work on that dual mechanism predates the brand name Mounjaro entirely, and the history of tirzepatide's development traces that research thread from discovery to clinical programme.

Between the laboratory and the licensed product, the drug moved through the standard regulatory phases: safety and tolerability studies, then dose-finding, then the large SURMOUNT trials enrolling thousands of adults across multiple countries. SURMOUNT-1 alone randomised 2,539 participants. The full SURMOUNT and SURPASS programmes combined covered more than 10,000 people. That scale of evidence is what gave regulators and NICE enough confidence to act.

One practical check you can do in under a minute: visit the GPhC pharmacy register and confirm that any online pharmacy you're considering holds a valid premises registration. It's a simple search and one of the most reliable ways to know whether a supply route is legitimate. Counterfeit weight-loss pens have been seized by the MHRA in significant quantities; a verifiable GPhC registration is a basic first filter.

Where things stand now, and what that means for private access

As of summer 2026, Mounjaro is a fully embedded part of the UK weight-management landscape. NHS commissioning is rolling out gradually, but waiting lists through specialist services remain long in many areas. For people who meet the private-prescription eligibility criteria (broadly, adults with a BMI of 30 or above, or 27 or above with a weight-related condition) a GPhC-registered online pharmacy like ours offers an alternative route that doesn't require a GP referral or a place on a waiting list.

That route still requires a real clinical assessment. Every consultation at our pharmacy is read by a GPhC-registered Independent Prescriber, not processed by an algorithm. Identity is verified, current weight is confirmed on video, and GP notification follows in line with GPhC guidance. If you want to understand what treatment through a private pharmacy typically costs, the Mounjaro pricing page gives an honest picture of what private treatment involves financially, including what legitimate pricing usually includes.

For anyone still weighing up whether Mounjaro is the right option at all, the broader weight-loss treatments page sets out the full range of licensed options we work with, and if you're researching the medicine from scratch, our guide explaining what Mounjaro is and how it works is a useful place to begin. A prescriber can only decide suitability after a full assessment, but it's a good place to start reading.